Skip to main content
SpringerLink
Log in

Cough Induced by Pharmacological ModulatiOn of the Renin-Angiotensin-Aldosterone System. Angiotensin Converting Enzyme Inhibitors And Angiotensin II Receptor Antagonists

  • Chapter
Angiotensin II Receptor Blockade Physiological and Clinical Implications

Part of the book series: Progress in Experimental Cardiology ((PREC,volume 2))

Summary

Dry cough is now recognized as a common side effect of ACE inhibitor therapy. When cough becomes bothersome, no alternative is better than substituting a different class of antihypertensive agents for the offending ACE inhibitors. Losartan potassium represents a new class of antihypertensive agents with a different mechanism of action: it directly blocks the effects of angiotensin (Ang) II at the receptor level, without affecting kininase II-related factors, such as the bradykinin system. As shown in the Losartan Cough Study, the incidence of cough related to a treatment with an AT1 type Ang II receptor antagonist, such as losartan, is significantly lower than that observed with lisinopril and is similar to that of HCTZ in patients with a rechallenged ACE-inhibitor cough. Ang II receptor antagonists represent a potential new treatment for hypertensive patients, which may be especially useful in patients in whom a pharmacological inhibition of RAAS is indicated, but who develop cough with ACE inhibitors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 259.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 329.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Brunner HR, Nussberger J, Waeber B. 1985. Effects of angiotensin converting enzyme inhibitor: a clinical point of view. J Cardiovasc Pharmacol 7(Suppl 4):73–81.

    Article  Google Scholar 

  2. The SOLVD Investigators. 1991. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325:293–302.

    Article  Google Scholar 

  3. The CONSENSUS Trial Study Group. 1987. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429–1435.

    Article  Google Scholar 

  4. Dzau VJ, Creager MA. 1987. Progress in angiotensin-converting enzyme inhibition in heart failure: rationale, mechanisms, and clinical responses. Cardiol Clin 7: 119–130.

    Google Scholar 

  5. Rush JE, Merrill DD. 1987. The safety and tolerability of lisinopril in clinical trials. J Cardiovasc Pharmacol 9(Suppl 3):S99–S107.

    Article  PubMed  Google Scholar 

  6. Davies RO, Irvin JD, Kramsch DK, Walker JF, Moncio F. 1984. Enalapril worldwild experience. Am J Med 77(Suppl 2A):23–35.

    PubMed  CAS  Google Scholar 

  7. Frolich ED, Cooper RA, Lewis EJ. 1984. Review of the overall experience of captopril in hypertension. Arch Intern Med 144:1441–1444.

    Article  Google Scholar 

  8. McFate Smith W, Kulaga SF, Moncloa F, Pingeon R, Walker JF. 1984. Overall tolerance and safety of enalapril. J Hypertens 2(Suppl 5):S113–S117.

    CAS  Google Scholar 

  9. Veterans Administration Cooperative Study group on Antihypertensive Agents. 1984. Low-dose captopril for the treatment of mild to moderate hypertension. I. Results of a 14-week trial. Arch Intern Med 144:1947–1953.

    Article  Google Scholar 

  10. Edwards CR, Padfield PL. 1985. Angiotensin-converting enzyme inhibitors: past, present, and bright future. Lancet 1:30–34.

    Article  PubMed  CAS  Google Scholar 

  11. Jenkins AC, Drelinski GR, Tadros SS, Groel JT, Fand R, Herczog SA. 1985. Captopril in hypertension: seven years later. J Cardiovasc Pharmacol 7(Suppl l):S96–S101.

    Article  PubMed  Google Scholar 

  12. DiBianco R. Adverse reactions with angiotensin converting enzyme (ACE) inhibitors 1986. Med Toxicol 1:122–141.

    Google Scholar 

  13. Irvin JD, Viau JM. 1986. Safety profiles of the angiotensin convering enzyme inhibitors captopril and enalapril. Am J Med 81(Suppl 4C):46–50.

    Article  PubMed  CAS  Google Scholar 

  14. Todd PA, Heel RC. 1986. Enalapril. A review of its pharmacodynamic and pharmacokinetics properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31:198–248.

    Article  PubMed  CAS  Google Scholar 

  15. Weber MA, Zusman RM. 1986. Converting enzyme inhibitors in the treatment of essential hypertension. Drug Ther 16:43–54.

    Google Scholar 

  16. Bolzano K, Arriaga J, Bernai R, Bernades H, Calderon JL, Debruyn J, Dienstl F, Drayer J, Goodfriend TL, Gross W. 1987. The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension. J Cardiovasc Pharmacol 9(Suppl 3):S43–S47.

    Article  PubMed  Google Scholar 

  17. Armayor GM, Lopez LM. 1988. Lisinopril: a new angiotensin-converting enzyme inhibitor. Drug Intell Clin Pharm 22:365–372.

    PubMed  CAS  Google Scholar 

  18. Brogden RN, Todd PA, Sorkin EM. 1988. Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 36:54–60.

    Article  Google Scholar 

  19. Graves H. 1986. A multicenter trial of enalapril in the treatment of essential hypertension. Clin Ther 9:24–38.

    Google Scholar 

  20. Inman WH, Rawson NS, Wilton LV, Pearce GL, Speirs CJ. 1988. Post-marketing surveillance of enalapril. I. Results of prescription-event monitoring. BMJ 297:826–829.

    Article  PubMed  CAS  Google Scholar 

  21. Kostis JB. 1988. Angiotensin converting enzyme inhibitors. II. Clinical use. Am Heart J 116:1591–1605.

    Article  PubMed  CAS  Google Scholar 

  22. Rumboldt Z, Marinkovic M, Drinovec J. 1988. Enalapril versus captopril: a double-blind multicentre comparison in essential hypertension. Int J Clin Pharmacol Res 8:181–188.

    PubMed  CAS  Google Scholar 

  23. Warner NJ, Rush JE. 1988. Safety profiles of the angiotensin-converting enzyme inhibitors. Drugs 35(Suppl 5):89–97.

    Article  PubMed  Google Scholar 

  24. Weber MA. 1988. Safety issues during antihypertensive treatment with converting enzyme inhibitors. Am J Med 84(Suppl 4A): 16–23.

    PubMed  CAS  Google Scholar 

  25. Arr SM, Woollard ML, Fairhurst G, Pippen CA, Rao SK, Cooper WD. 1985. Safety and efficacy of enalapril in essential hypertension in the elderly. Br J Clin Pharmacol 20:279P–280P.

    Google Scholar 

  26. Jenkins AC, Knill JR, Dreslinki GR. 1985. Captopril in the treatment of elderly hypertensive patient. Arch Intern Med 145:2029–2031.

    Article  PubMed  CAS  Google Scholar 

  27. Creisson C, Baulac L, Lenfant B. 1986. Captopril/hydrochlorothiazide combination in elderly patients with mild-moderate hypertension. A double-blind, randomized, placebo-controlled study. Postgrad Med J 62(Suppl 1):139–141.

    PubMed  Google Scholar 

  28. Lacourcière Y, Brunner H, Irwin R, Karlberg BE, Ramsay LE, Snavely DB, Dobbins TW, Faison EP, Nelson EB and the Losartan Cough Study Group. 1994. Effects of modulators of the renin-angiotensin-aldosterone system on cough. J Hypertens 12:1387–1393.

    PubMed  Google Scholar 

  29. Lacourcière Y, Lefebvre J. 1995. Modulation of the renin-angiotensin-aldosterone system and cough. Can J Cardiol 11(Suppl F):33F–39F.

    PubMed  Google Scholar 

  30. Sesoko S, Kaneko Y. 1985. Cough associated with the use of captopril (letter). Arch Intern Med 145:1524.

    Article  PubMed  CAS  Google Scholar 

  31. Israili ZH, Hall WD. 1992. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and physiopathology. Ann Intern Med 117(3):234–242.

    Article  PubMed  CAS  Google Scholar 

  32. Just PM. 1989. The positive association of cough with angiotensin-converting enzyme inhibitors. Ann Pharmacoth 9:82–87.

    CAS  Google Scholar 

  33. Inman WH. 1986. Enalapril-induced cough (letter). Lancet 2:1218.

    Article  PubMed  CAS  Google Scholar 

  34. Webb DJ, Benjamin N, Collier JG, Robinson BF. 1986. Enalapril-induced cough (letter). Lancet 2:1094.

    Article  PubMed  CAS  Google Scholar 

  35. Coulter DM, Edwards IR. 1987. Cough associated with captopril and enalapril. Br Med J (Clin Res Ed) 294:1521–1523.

    Article  CAS  Google Scholar 

  36. Goldzer RC, Lilly LS, Solomon HS. 1988. Prevalence of cough during angiotensin-converting enzyme inhibitor therapy (letter). Am J Med 85:887.

    Article  Google Scholar 

  37. Gibson GR. 1989. Enalapril induced cough. Arch Intern Med 149:2701–2703.

    Article  PubMed  CAS  Google Scholar 

  38. Strocchi E, Valtancoli G, Ambrosioni E. 1989. The incidence of cough during treatment with angiotensin converting enzyme inhibitors. J Hypertens 7(Suppl 6):S308–S309.

    CAS  Google Scholar 

  39. Poole MD, Postma DS. 1991. Characterization of cough associated with angiotensin-converting enzyme inhibitors. Otolaryngol Head Neck Surg 105:714–716.

    PubMed  CAS  Google Scholar 

  40. Capella D, Torres F, Avila P, Moreno V, Laporte JR. 1991. Cough caused by angiotensin-converting enzyme inhibitors. A series of cases collected by spontaneous notification of adverse reactions. Med Clin (Barc) 96:126–128.

    CAS  Google Scholar 

  41. McNally EM. 1987. Cough due to captopril. West J Med 146:226–228.

    PubMed  CAS  Google Scholar 

  42. Faison EP, Nelson EB, Irvin JD. 1991. Profile of angiotensin converting enzyme inhibitor (ACE I) associated cough: Incidence and clinical characteristics. Amer J Hypertens 4(5;Pt2):28A.

    Google Scholar 

  43. Witchitz S, Beaufils M, Liote H, Petroff C. 1989. Complications respiratoires des inhibiteurs de l’enzyme de conversion. (Respiratory complications of converting-enzyme inhibitors) (letter). Presse Med 18(17):896.

    PubMed  CAS  Google Scholar 

  44. Lernhardt EB, Ziegler MG. 1988. Cough caused by cilazapril. Am J Med Sci 296(2):119–120.

    Article  PubMed  CAS  Google Scholar 

  45. Ollivier JP, Ducrocq MB, Droniou J. 1988. Un Effet secondaire des inhibiteurs de l’enzyme de conversion: La Toux. (A side-effect of angiotensin-converting enzyme inhibitors: Cough). Presse Med 16:759–761.

    Google Scholar 

  46. De Groote P, Millaire A, Aisenfarb JC, Marquand A, Ducloux G. 1988. Toux et inhibiteurs de l’enzyme de conversion de l’angiotensine. (Cough and angiotensin-converting enzyme inhibitors). Ann Cardiol Angeiol 37(5):251–253.

    Google Scholar 

  47. Dreslinski GR. 1987. Incidence of cough associatd with captopril therapy (letter). West J Med 146:622.

    PubMed  CAS  Google Scholar 

  48. Strump KO, Lolloch R, Overlack A. 1984. Captopril and enalapril: Evaluation of therapeutic efficacy and safety. Pract Cardiol 10:111–124.

    Google Scholar 

  49. Fuller RW, Choudry NB. 1987. Increased cough reflex associated with angiotensin-converting enzyme inhibitor cough. Br Med J 295:1025–1026.

    Article  CAS  Google Scholar 

  50. Lefebvre J, Poirier L, Lacourcière Y. 1992. Prospective trial on captopril-related cough. Ann Pharmacol 26:161–164.

    CAS  Google Scholar 

  51. Yeo WW, Ramsay LE. 1990. Persistent dry cough with enalapril: incidence depends on method used. J Hum Hypertens 4:517–520.

    PubMed  CAS  Google Scholar 

  52. Faison EP, Nelson EB, Irvin JD. 1991. Profile of angiotensin converting enzyme inhibitor (ACE I) associated with cough: incidence and clinical characteristics (abstract 29). Am J Hypertens 4(Suppl):28A.

    Google Scholar 

  53. Chalmers D, Dombey SL, Lawson DH. 1987. Post-marketing surveillance of captopril (for hypertension): a preliminary report. Br J Clin Pharmacol 24(3):343–349.

    Article  PubMed  CAS  Google Scholar 

  54. Town GI, Hallwright GP, Maling TJB, O’Donnell TV. 1987. Angiotensin-converting enzyme inhibitors and cough. N Z Med J 100:161–163.

    PubMed  CAS  Google Scholar 

  55. Fletcher AE, Palmer AJ, Bulpitt CJ. 1994. Cough with angiotensin converting enzyme inhibitors: How much a problem? J Hypertens 12(Suppl 2):S43–S47.

    CAS  Google Scholar 

  56. Os I, Bratland B, Dahlöf B, Gisholt K, Syvertsen JO, Tretli S. 1992. Female sex as an important determination of lisinopril-induced cough (letter). Lancet 339:372.

    Article  PubMed  CAS  Google Scholar 

  57. Moore N, Noblet C, Joannides R, Ollagnier M, Imbs JL, Lagier G. 1933. On behaif of the French Pharmacovigilance System: Cough and ACE inhibitors (letter). Lancet 341:61.

    Article  Google Scholar 

  58. Fletcher AE, Bulpitt CJ, Chase D, Collins W, Furberg CD, Goggin TK, Hewett AJ, Neiss AM. 1992. Quality of life on three antihypertensive treatments: cilazapril, atenolol, nifedipine. Hypertension 19:499–507.

    Article  PubMed  CAS  Google Scholar 

  59. Simon SH, Black HR, Moser M, Berland WE. 1992. Cough and ACE inhibitors. Arch Intern Med 152:1698–1700.

    Article  PubMed  CAS  Google Scholar 

  60. Hood S, Nicholls MG, Gilchrist NL. 1987. Cough with angiotensin-converting inhibitors. N Z Med J 100:6–7.

    PubMed  CAS  Google Scholar 

  61. Nicholls GN, Gilchrist NL. 1987. Sulindac and cough induced by converting enzyme inhibitors (letter). Lancet 1:872.

    PubMed  CAS  Google Scholar 

  62. David D and The Fosinopril Cough Study Group. 1994. Multicenter, doubleblind, randomized trial comparing fosinopril to enalapril in patients with previous angiotensin converting enzyme cough, (abstract 512). Presentd at the 24thScientific Meeting of the International Society of Hypertension, Melbourne, Australia.

    Google Scholar 

  63. Skidgel RA, Erdos EG. 1987. Cleavage of peptide bonds by angiotensin I converting enzyme. Agents Actions 22(Suppl):589–596.

    Google Scholar 

  64. Kaufman MP, Coleridge HM, Coleridge JC, Baker DG. 1980. Bradykinin stimulate afferent vagal C-fibers in intrapulmonary airways of dogs. J Appl Physiol 48:511–517.

    PubMed  CAS  Google Scholar 

  65. Varonier HS, Panzani R. 1968. The effect of inhalations of bradykinin on healthy and atopic (asthmatic) children. Int Arch Allergy Immunol 34:293–296.

    Article  CAS  Google Scholar 

  66. Ferner RE, Simpson JM, Rawlins MD. 1987. Effects of intradermal bradykinin after inhibition of angiotensin converting enzyme. Br Med J (Clin Res Ed) 294:1119–1120.

    Article  CAS  Google Scholar 

  67. Greenberg R, Osman GH Jr, O’Keefe EH, Antonaccio MJ. 1979. The effects of captopril (SQ 14,225) on bradykinin-induced bronchoconstriction in the anaesthetised guinea pig. Eur J Pharmacol 57:287–294.

    Article  PubMed  CAS  Google Scholar 

  68. Fogari R, Zoppi A, Tettamanti F, Malamani GD, Tinelli C, Salvetti A. 1992. Effects of nifedipine and indomethacin on cough induced by angiotensin converting enzyme inhibitors: A double-blind, randomized, cross-over study. J Cardiovasc Pharmacol 19:670–673.

    PubMed  CAS  Google Scholar 

  69. Regoli D, Barabe J. 1980. Pharmacology of bradykinin and related kinins. Pharmacol Rev 32: 1–46.

    PubMed  CAS  Google Scholar 

  70. Goetzl EJ. 1984. Asthma: new mediators and old problems (editorial). N Eng J Med 311:252–253.

    Article  CAS  Google Scholar 

  71. Dixon CM, Fuller RW, Barnes PJ. 1987. The effects of the angiotensin converting enzyme inhibitor, ramipril, on bronchial response to inhaled histamine and bradykinin in asthamatic subjects. Br J Clin Pharmacol 23:91–93.

    Article  PubMed  CAS  Google Scholar 

  72. Morice AH, Lowry R, Brown MJ, Higenbottam T. 1987. Angiotensin-converting enzyme and the cough reflex. Lancet 2(8568):1116–1118.

    Article  PubMed  CAS  Google Scholar 

  73. Meeker DP, Wiedemann HP. 1990. Drug-induced bronchospasm. Clinics in Chest Medicine 11(1):163–175.

    PubMed  CAS  Google Scholar 

  74. Korpas J, Tomori Z. 1979. Physiology of the cough reflex. Cough and other respiratory reflexes. S. Karger Publisher 15–18.

    Google Scholar 

  75. Kaufman J, Casanova JE, Riendl P, Schlueter DP. 1989. Bronchial hyperactivity and cough due to angiotensin-converting enzyme inhibitors. Chest 95(3):544–548.

    Article  PubMed  CAS  Google Scholar 

  76. Boulet LP, Milot J, Lampron N, Lacourcière Y. 1989. Pulmonary function and airway responsiveness during long-term therapy with captopril. JAMA 261:413–416.

    Article  PubMed  CAS  Google Scholar 

  77. Yeo WW, Ramsay LE, Morice AH. 1991. ACE inhibitor cough: A genetic link? (letter) Lancet 337:187.

    Article  PubMed  CAS  Google Scholar 

  78. Kreft-Jais C, Laforest L, Bonnardeaux A, Jeunemaître X. 1994. No relation between the insertion/ deletion (I/D) polymorphism of the angiotensin I converting enzyme (ACE) gene and ACE-inhibitor cough, (abstract 519). J Hypertens 12(Suppl 3):S93.

    Google Scholar 

  79. O’Kane KPJ, Johnstone HA, Webb DJ. 1994. The risk of ACE inhibitor cough is not associated with ACE genotype, (abstract 524). J Hypertens 12(Suppl 3):S94.

    Google Scholar 

  80. Turgeon J, Roy S, Belley D, Poirier L, Robitaille NM. 1994. Link between ACE inhibitor associated cough and XBA I DNA restriction fragments of mutant alteles of CYP2D6. (abstract 85). J Hypertens 12(Suppl 3):S154.

    Google Scholar 

  81. Wong PC, Price WA, Chiu AT, Duncia JV, Carini DJ, Wexler RR, Johnson AL, Timmermans PB. 1990. Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Therap 252:719–725.

    CAS  Google Scholar 

  82. Lacourcière Y, Lefebvre J, Nakhle G, Faison EP, Snavely DB, Nelson EB. 1994. Association between cough and angiotensin converting enzyme inhibitors versus angiotensin II antagonists: the design of a prospective, controlled study. J Hypertens 12(Suppl 2):S49–S53.

    Google Scholar 

  83. Fletcher AE, Bulpitt CJ, Hawkins CM, Havinga TK, Tenberge BS, May JF, Schuurman FH, van der Veur E, We sseling H. 1990. Quality of life on antihypertensive therapy; a randomized double-blind controlled trial of captopril and atenolol. J Hypertens 8:463–466.

    Article  PubMed  CAS  Google Scholar 

  84. Nelson DE, Moyse DM, O’Neil JM, Boger RS, Glassman HN, Kleinen HD. 1993. Renin inhibitor, Abott-72517, does not induce characteristic angiotensin converting enzyme inhibitor cough (Abstract 1934). Circulation 1:36.

    Google Scholar 

  85. Reisin L, Schneeweiss A. 1992. Complete spontaneous remission of cough induced by ACE-inhibitors during chronic therapy in hypertensive patients. J Hum Hypertens 6:333–335.

    PubMed  CAS  Google Scholar 

  86. Stroller JR, Elghazawi A, Metha AL, Vidt DG. 1988. Captopril-induced cough. Chest 93(3):659–661.

    Article  Google Scholar 

  87. Karlberg BE. 1993. Cough and inhibition of the renin-angiotensin system. J Hypertens 11(3):S49–S52.

    CAS  Google Scholar 

  88. Lindgren BR, Anderson RG. 1989. Angiotensin-converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. A research review. Med Toxicol Adverse Drug Exp 4:369–380.

    Article  PubMed  CAS  Google Scholar 

  89. Thysell H, Anderson KE, Andersen SL, Ekman R. 1988. Angiotensin converting-enzyme inhibition, cough and the serum concentration of substance P. Eur J Clin Pharmacol 34:649–650.

    Article  PubMed  CAS  Google Scholar 

  90. Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM. 1993. Comparison of angiotensin-converting enzyme inhibition with angiotensin 11 receptor antagonism in the human forearm. J Cardiovasc Pharmacol 22:579–584.

    Article  PubMed  CAS  Google Scholar 

  91. Smith MC, Barrows S, Shahinfar S, Simpson RL, Weigel K, Dunn MJ. 1993. The effect of the nonpeptide All antagonist losartan on systemic blood pressure and renal and extrarenal prostaglandin (PG) production in women with essential hypertension (abstract). J Amer Soc Nephrol 4(3):540.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertension Research Unit, Le Centre Hospitalier Universitaire de Québec, Québec, Canada

    Yves Lacourcière & Jean Lefebvre

Authors
  1. Yves Lacourcière
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jean Lefebvre
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Cardiovascular Sciences St. Boniface General Hospital Research Centre Faculty of Medicine, University of Manitoba, Winnipeg, Canada

    Naranjan S. Dhalla Ph.D., M.D. (Hon.) (Distinguished Professor and Director MRC Group in Experimental Cardiology), Peter Zahradka Ph.D. (Associate Professor), Ian M. C. Dixon Ph.D. (Assistant Professor) & Robert E. Beamish M.D. (Professor Emeritus) (Distinguished Professor and Director MRC Group in Experimental Cardiology),  (Associate Professor),  (Assistant Professor) &  (Professor Emeritus)

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer Science+Business Media New York

About this chapter

Cite this chapter

Lacourcière, Y., Lefebvre, J. (1998). Cough Induced by Pharmacological ModulatiOn of the Renin-Angiotensin-Aldosterone System. Angiotensin Converting Enzyme Inhibitors And Angiotensin II Receptor Antagonists. In: Dhalla, N.S., Zahradka, P., Dixon, I.M.C., Beamish, R.E. (eds) Angiotensin II Receptor Blockade Physiological and Clinical Implications. Progress in Experimental Cardiology, vol 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-5743-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-5743-2_10

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7631-6

  • Online ISBN: 978-1-4615-5743-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation